Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PLUR vs STRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STRO Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–3 Matrix Metrics)

STRO Overall Winner 6-Pillar Tally: PLUR 2 – 2 STRO (2 Tie) Matrix Metrics: PLUR 3 – 6 STRO

As of Nov 17, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas STRO carries 45.1/100 (HOLD) at $8.90 (10.0x Forward P/E, -254.7% operating margin).

  • Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUR vs STRO
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08
STRO NASDAQ Head-to-Head Winner
Sutro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
$8.90
-4.51% 1D
Market Cap $163.0M
TTM Revenue $45M
Forward P/E 10.0x
Beta / 30D Vol 1.65β · 80% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.6%), weak momentum, RSI 34
RSI-14: 33.9 · SMA20: $9.58 · SMA50: $12.76

6-Pillar Scorecard Institutional Category Breakdown (PLUR 2 – 2 STRO)

Columns: Metric · PLUR · STRO
1. Valuation Multiples PLUR
Forward P/E 3.6x 10.0x
Trailing P/E 3.6x 10.0x
PEG Ratio N/M N/M
EV / Revenue 44.6x 3.6x
2. Growth & Scale STRO
Revenue Growth (YoY) -15.8% -6.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.0M $45M
Market Cap $15.1M $163.0M
3. Profitability & Quality PLUR
Gross Margin 44.6% N/A
Operating Margin -2454.5% -254.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1022.0% -1810.0%
4. Balance Sheet & Cash Flow STRO
Cash Generation (TTM) -$22M -$109M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Debt -1810.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 122.4% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUR (3) vs STRO (6)
Institutional Metric PLUR STRO Criterion Row Edge
Market Capitalization
Scale
$15.1M $163.0M Larger Scale STRO
Trailing P/E Ratio
Valuation
3.6x 10.0x Lower Multiple PLUR
Forward P/E Ratio
Valuation
3.6x 10.0x Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-15.8% -6.1% Higher Growth STRO
Operating Margin (TTM)
Profitability
-2454.5% -254.7% Higher Margin STRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1022.0% -1810.0% Higher ROE PLUR
52-Week Range Position
Momentum
2% ($1–$5) 19% ($1–$44) Stronger Trend STRO
Beta / 30D Volatility
Risk Regime
0.80β · 102% Vol 1.65β · 80% Vol Lower Realized Risk STRO
Unified Institutional Score
Composite Signal
28.8 / 100 (SELL) 45.1 / 100 (HOLD) Higher Composite STRO
Trailing 12M Revenue (USD)
Operating Scale
$1.0M $45M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 44.6x EV/Rev N/M PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($30M Net Debt) -$109M EBITDA (-1810.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +32.01 pp
PLUR: +11.09% · STRO: -20.92%
3M Horizon PLUR +13.04 pp
PLUR: -46.34% · STRO: -59.38%
6M Horizon PLUR +9.38 pp
PLUR: -62.52% · STRO: -71.9%
1Y Horizon STRO +959.17 pp
PLUR: -75.53% · STRO: +883.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUR vs STRO. Trailing 12-month operating profitability (PLUR -2454.5% vs STRO -254.7%) and valuation multiples (PLUR 3.6x vs STRO 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.

PLUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin44.6%
Op. Margin-2454.5%
ROE / Fwd P/E-1022.0% · 3.6x
STRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$45M
Gross MarginN/A
Op. Margin-254.7%
ROE / Fwd P/E-1810.0% · 10.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 122.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $163.0M market capitalization and -254.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLUR vs STRO Key Questions & Quantitative Answers

As of Nov 17, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas STRO carries 45.1/100 (HOLD) at $8.90 (10.0x Forward P/E, -254.7% operating margin). Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STRO leads the Growth & Scale pillar: PLUR posts -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin), compared with STRO at -6.1% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (N/A gross margin, -254.7% operating margin). On trailing 12-month operating scale, PLUR generates $1.0M in USD-normalized revenue versus $45M for STRO. In operating R&D and SG&A reinvestment, PLUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STRO.

PLUR screens cheaper on headline valuation multiples. PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin), whereas STRO trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUR (-1022.0% ROE) versus STRO (-1810.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk). By comparison, STRO carries 122.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.